Kiniksa Reports First Quarter 2020 Financial Results and Highlights Recent Corporate and Pipeline Activity
April 28, 2020 07:30 ET
|
Kiniksa Pharmaceuticals, Ltd.
– Financial guidance and clinical timelines for rilonacept, mavrilimumab, vixarelimab and KPL-404 remain intact amid COVID-19 pandemic –– Mavrilimumab treatment protocol in COVID-19 pneumonia and...
Kiniksa Announces Early Evidence of Treatment Response with Mavrilimumab in 6 Patients with Severe COVID-19 Pneumonia and Hyperinflammation
March 31, 2020 08:14 ET
|
Kiniksa Pharmaceuticals, Ltd.
- All 6 patients treated with mavrilimumab showed resolution of fever and did not progress to mechanical ventilation; follow-on controlled study in Italy planned - - Consortium of U.S. academic sites...
Kiniksa Presents Preclinical Data on the Role of GM-CSF in GCA at the 2019 ACR/ARP Annual Meeting
November 12, 2019 16:01 ET
|
Kiniksa Pharmaceuticals, Ltd.
- Mavrilimumab suppresses pathogenic immune responses in a validated in vivo model of medium and large vessel vasculitis - - Additional human ex vivo data support rationale for targeting GM-CSF in...
Kiniksa Reports Third Quarter 2019 Financial Results and Highlights Recent Corporate and Pipeline Activity
October 28, 2019 16:01 ET
|
Kiniksa Pharmaceuticals, Ltd.
– Clinical data readouts expected throughout 2020 for rilonacept, mavrilimumab, KPL-716 and KPL-404 –– Operating plan funded into 2H 2021; no current plan to raise additional capital prior to...
Kiniksa Reports Second Quarter 2019 Financial Results and Highlights Recent Corporate and Pipeline Activity
August 12, 2019 16:02 ET
|
Kiniksa Pharmaceuticals, Ltd.
– Rilonacept pivotal Phase 3 study dosing patients in the U.S., Australia, Israel and Italy; expect to present final Phase 2 data this year – – Mavrilimumab global Phase 2 study dosing patients in...
Kiniksa Presents Preclinical Data on the GM-CSF Signaling Pathway in Temporal Arteries of GCA Patients at the Annual European Congress of Rheumatology
June 12, 2019 07:30 ET
|
Kiniksa Pharmaceuticals, Ltd.
- Preclinical data support rationale for targeting GM-CSF in GCA – - Mavrilimumab shows biological effect on genes relevant to GCA pathophysiology in ex vivo cultures of GCA arteries – HAMILTON,...
Kiniksa to Present Preclinical Data on the GM-CSF Signaling Pathway in Temporal Arteries of GCA Patients at EULAR 2019
May 30, 2019 16:01 ET
|
Kiniksa Pharmaceuticals, Ltd.
HAMILTON, Bermuda, May 30, 2019 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals, Ltd. (Nasdaq: KNSA) (“Kiniksa”), a biopharmaceutical company focused on discovering, acquiring, developing and...
Kiniksa Reports First Quarter 2019 Financial Results and Highlights Recent Corporate and Pipeline Activity
May 02, 2019 07:30 ET
|
Kiniksa Pharmaceuticals, Ltd.
– First patient dosed in Phase 2a trial of KPL-716 in prurigo nodularis– Upcoming presentations at SID, ISPOR and EULAR scientific conferences on KPL-716, rilonacept and mavrilimumab, respectively–...
Kiniksa Announces Active U.S. Investigational New Drug Application for Mavrilimumab
January 03, 2019 07:30 ET
|
Kiniksa Pharmaceuticals, Ltd.
HAMILTON, Bermuda, Jan. 03, 2019 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals, Ltd. (Nasdaq: KNSA) (“Kiniksa”), a biopharmaceutical company with a pipeline of five product candidates across various...